Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT: TSA-T for Pediatric Brain Tumors
NCT06193759Phase 1Recruiting
- Sponsor
- Children's National Research Institute
- Start
- Sep 2024
- Primary completion
- Dec 2030
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of TSA-T in embryonal brain tumor and ependymoma (2 arms), sponsored by Children's National Research Institute. Primary endpoints: Dose Limiting Toxicities at 42 days, Maximum-Tolerated Dose at 42 days and 2 more. Started Sep 2024; status: recruiting.
02
Drugs
TSA-T
03
Conditions
embryonal brain tumorependymoma
Beyond the preview
Go deeper on NCT06193759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193759.